Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2017 (2017), Article ID 8103726, 7 pages
https://doi.org/10.1155/2017/8103726
Research Article

Interspecies In Vitro Evaluation of Stereoselective Protein Binding for 3,4-Methylenedioxymethamphetamine

1Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
2USAINS Biomics, Bangunan Eureka, Universiti Sains Malaysia, 11800 Minden, Pulau Pinang, Malaysia
3Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Correspondence should be addressed to Siew Hua Gan; ym.msu@naghs

Received 18 November 2016; Revised 14 February 2017; Accepted 20 February 2017; Published 2 March 2017

Academic Editor: Paula G. De Pinho

Copyright © 2017 Wan Raihana Wan Aasim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UN, “United Nations Office on Drugs and Crime: Wold Drug Report,” 2015.
  2. A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado, “The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'),” Pharmacological Reviews, vol. 55, no. 3, pp. 463–508, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Vegting, L. Reneman, and J. Booij, “The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies,” Psychopharmacology, vol. 233, no. 19-20, pp. 3473–3501, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Kalant, “The pharmacology and toxicology of ‘ecstasy’ (MDMA) and related drugs,” Canadian Medical Association Journal, vol. 165, no. 7, pp. 917–928, 2001. View at Google Scholar
  5. M. R. Meyer, F. T. Peters, and H. H. Maurer, “The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers,” Drug Metabolism and Disposition, vol. 36, no. 11, pp. 2345–2354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K.-P. Kreth, K.-A. Kovar, M. Schwab, and U. M. Zanger, “Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs,” Biochemical Pharmacology, vol. 59, no. 12, pp. 1563–1571, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. A. E. Schwaninger, M. R. Meyer, A. J. Barnes et al., “Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans,” Biochemical Pharmacology, vol. 83, no. 1, pp. 131–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Glennon, M. Yousif, and G. Patrick, “Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs,” Pharmacology, Biochemistry and Behavior, vol. 29, no. 3, pp. 443–449, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. L. E. Baker and M. M. Taylor, “Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination,” Pharmacology Biochemistry and Behavior, vol. 57, no. 4, pp. 737–748, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. F. T. Peters, N. Samyn, M. Wahl, T. Kraemer, G. De Boeck, and H. H. Maurer, “Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS,” Journal of Analytical Toxicology, vol. 27, no. 8, pp. 552–559, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Pizarro, M. Farré, M. Pujadas et al., “Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine),” Drug Metabolism and Disposition, vol. 32, no. 9, pp. 1001–1007, 2004. View at Google Scholar · View at Scopus
  12. N. Pizarro, A. Liebaria, S. Cano et al., “Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 17, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. K. Fallon, A. T. Kicman, J. A. Henry, P. J. Milligan, D. A. Cowan, and A. J. Hutt, “Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (Ecstasy) in humans,” Clinical Chemistry, vol. 45, no. 7, pp. 1058–1069, 1999. View at Google Scholar · View at Scopus
  14. A. E. Steuer, C. Schmidhauser, Y. Schmid, A. Rickli, M. E. Liechti, and T. Kraemer, “Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans,” Drug Metabolism and Disposition, vol. 43, no. 12, pp. 1864–1871, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Sarkar and L. Schmued, “Neurotoxicity of ecstasy (MDMA): an overview,” Current Pharmaceutical Biotechnology, vol. 11, no. 5, pp. 460–469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Kraemer and H. H. Maurer, “Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives,” Therapeutic Drug Monitoring, vol. 24, no. 2, pp. 277–289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. F. T. Peters, N. Samyn, C. T. J. Lamers et al., “Drug testing in blood: Validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA,” Clinical Chemistry, vol. 51, no. 10, pp. 1811–1822, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Escuder-Gilabert, M. A. Martínez-Gómez, R. M. Villanueva-Camañas, S. Sagrado, and M. J. Medina-Hernández, “Microseparation techniques for the study of the enantioselectivity of drug-plasma protein binding,” Biomedical Chromatography, vol. 23, no. 3, pp. 225–238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Fitos, J. Visy, and J. Kardos, “Stereoselective kinetics of warfarin binding to human serum albumin: effect of an allosteric interaction,” Chirality, vol. 14, no. 5, pp. 442–448, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Paliwal, D. E. Smith, S. R. Cox, R. R. Berardi, V. A. Dunn-Kucharski, and G. H. Elta, “Stereoselective, competitive, and nonlinear plasma protein binding of ibuprofen enantiomers as determined in vivo in healthy subjects,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 21, no. 2, pp. 145–161, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Dubois, F. Lapicque, M. Abiteboul, and P. Netter, “Stereoselective protein binding of ketoprofen: effect of albumin concentration and of the biological system,” Chirality, vol. 5, no. 3, pp. 126–134, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. E. R. Garrett, K. Seyda, and P. Marroum, “High performance liquid chromatographic assays of the illicit designer drug ‘Ecstasy’, a modified amphetamine, with applications to stability, partitioning and plasma protein binding,” Acta Pharmaceutica Nordica, vol. 3, no. 1, pp. 9–14, 1991. View at Google Scholar
  23. W. A. Wan Raihana, S. H. Gan, and S. C. Tan, “Stereoselective method development and validation for determination of concentrations of amphetamine-type stimulants and metabolites in human urine using a simultaneous extraction-chiral derivatization approach,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 879, no. 1, pp. 8–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. H. Cohen, “Plasma protein-binding methods in drug discovery,” in Optimization in Drug Discovery: In Vitro Methods, pp. 111–122, Humana Press, Totowa, NJ, USA, 2004. View at Google Scholar
  25. N. Dow, “Determination of compound binding to plasma proteins,” in Current Protocols in Pharmacology, chapter 7, unit 7.5, John Wiley & Sons, 2006. View at Publisher · View at Google Scholar
  26. K. M. Clauwaert, J. F. Van Bocxlaer, E. A. De Letter, S. Van Calenbergh, W. E. Lambert, and A. P. De Leenheer, “Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine,” Clinical Chemistry, vol. 46, no. 12, pp. 1968–1977, 2000. View at Google Scholar · View at Scopus